engleski

Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients.

In this study we presented dynamics of tumor marker CYFRA 21-1 level that is evaluated as a response to therapy (surgery or chemotherapy) in 500 NSCLC patients. Serum level of CYFRA 21-1 was measured with electrochemiluminescence method using fully automated system Elecsys 2010 (Roche Diagnostics). The level of CYFRA 21-1 in NSCLC patients was determined before and after the therapy. In 95% surgically treated patients we observed a significant decrease of CYFRA 21-1 level after the therapy to the average level of healthy population (p<0.001). In 5% patients the increase of CYFRA 21-1 level was observed after the surgery, which indicated the tumor biological activity. This allowed the clinicians to apply an additional therapy. From 141 patients who underwent surgery followed by chemotherapy in 35% CYFRA 21-1 level indicated the inefficiency of therapy, which was also proved clinically. This allowed the clinicians to replace applied chemotherapy.Introducing the protocol including the evaluation of CYFRA 21-1 level before and after therapy we proved the contribution of tumor marker CYFRA 21-1 to the selection and control of therapy and the assessment of therapy efficiency.

CYFRA-21-1 tumor marker; longitudinal follow up; responce to therapy; NSCLC

nije evidentirano